Background: Cancer remains a leading cause of death globally, necessitating the identification of prognostic biomarkers to guide treatment decisions. The Royal Marsden Hospital (RMH) score, based on readily available blood tests and clinical features, has emerged as a prognostic tool, although its performance across variable clinical scenarios is not thoroughly delineated. Therefore, we aimed to systematically assess the association between RMH score and survival in cancer patients. Methods: We conducted a systematic literature search across Pubmed, Scopus, and Web of Science databases for studies published up to 15 February 2024. We performed a meta-analysis with the generic inverse variance method with a random-effects model and reported hazard ratios (HR) with 95% confidence intervals (CI). Results: Nineteen studies encompassing 127,230 patients were included. A higher RMH score was significantly associated with worse overall survival (OS) (HR: 2.09, 95% CI: 1.87–2.33,p< 0.001) and progression-free survival (PFS) (HR: 1.80, 95% CI: 1.48–2.18,p< 0.001). This association was consistent across various subgroups, including study population (clinical trial vs. real-world cohort), geographic region, and tumor type. Conclusion: This meta-analysis, including over a hundred thousand patients, demonstrates a negative association between a higher RMH score and survival in cancer patients. The RMH score holds promise as a readily available prognostic tool across diverse cancer types and clinical settings. Future research should focus on validating and refining this score to aid clinical decision-making.
背景：癌症仍是全球主要死亡原因，因此需要识别预后生物标志物以指导治疗决策。皇家马斯登医院评分基于易获取的血液检测和临床特征，已成为一种预后评估工具，但其在不同临床场景中的表现尚未得到充分阐明。本研究旨在系统评估癌症患者RMH评分与生存率之间的关联。 方法：我们系统检索了截至2024年2月15日发表在PubMed、Scopus和Web of Science数据库中的相关研究。采用随机效应模型的通用逆方差法进行荟萃分析，并报告风险比及其95%置信区间。 结果：共纳入19项研究，涵盖127,230例患者。较高的RMH评分与较差的总生存期显著相关，风险比为2.09，95%置信区间为1.87-2.33；同时与较差的无进展生存期显著相关，风险比为1.80，95%置信区间为1.48-2.18。这种关联在不同亚组中表现一致，包括研究人群、地理区域和肿瘤类型等维度。 结论：这项涵盖超十万患者的荟萃分析表明，较高的RMH评分与癌症患者较差的生存预后呈负相关。RMH评分有望成为跨癌种和临床场景的便捷预后评估工具。未来研究应着重验证并优化该评分体系，以辅助临床决策制定。
肿瘤(癌症)患者之家